+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Asia - Pacific Sodium-dependent Glucose Co-transporter 2 (SGLT2) Market - Growth, Trends, and Forecast (2019 - 2024)

  • PDF Icon


  • 90 Pages
  • March 2019
  • Region: Asia Pacific
  • Mordor Intelligence
  • ID: 4772056
UP TO OFF until Sep 30th 2023
Market Overview
  • The SGLT2 class of drugs includes Jardiance, Fraxiga, Inovokana, and Suglat. Suglat is only available in Japan and South Korea. The Asia - Pacific sodium-dependent glucose cotransporter 2 (SGLT2) market (hereafter, referred to as the market studied) is expected to witness a tremendous growth during the forecast period (2019-2024), with a CAGR of 14.7% mainly due to drug Jardiance and Farxiga/Forxiga.
  • Jardiance is a once-daily oral medication that is used to control blood glucose levels in people with type-2 diabetes. The underlying mechanism behind the SGLT2 drugs is they inhibit reabsorption of glucose in the kidney and therefore, lower blood sugar.

Scope of the Report

The market is segmented by Drug (Invokana, Jardiance, Farxiga/Forxiga, and Suglat) and Geography

Key Market Trends

SGLT2 Market is Expected to Reach USD 1.1 billion Revenue by 2019.
  • Though the growing global type-2 diabetic population promotes the growth of SGLT2 drugs, the Asia - Pacific region accounts for a significant market share globally, due to the region’s high type-2 diabetic population.
  • As there is an exponential growth of diabetes population year-on-year, especially Type-2 diabetic patients, new innovative drugs are coming up in the market for the ease of access to the patients.
  • Jardiance accounted for 47% of market share in the Asia - Pacific SGLT2 market, with 0.4 billion in the year 2018.
  • Suglat (Ipragliflozin) is marketed only in Japan and South Korea. It contributed to a 14% share in the Asia - Pacific SGLT2 market.
  • The market growth for the drug Invonkana has been decreasing when compared to other SGLT2 class of drugs, due to a large number of side effects, such as increasing weight and high cardiovascular risks for the patients.

China and India are Having more than 40% of Share in the Asia - Pacific SGLT2 Market.
  • China and India have the highest market share in the Asia - Pacific SGLT2 market with 29.30% and 16.74%, respectively.
  • The diabetes population of China and India is expected to reach 123 and 76 million, respectively by 2019.
  • Japan has more local players than global players. Mitsubishi Tanabe Pharma Corporate in Japan and South Korea markets Invokana drug, and where the same drug is being marketed by Janssen Pharmaceuticals in the rest of the regions in Asia - Pacific.
  • With the increase in diabetes population, the need and demand for diabetes drugs are expected to increase in the Asia - Pacific region. The other factors, such as better adoption than other therapies and government initiatives, are driving the diabetes drugs market. Thus, the sales of SGLT2 is high in these regions.

Competitive Landscape
  • The Asia-Pacific SGLT2 market is highly consolidated, with a few significant manufacturers having a global and regional market presence.
  • The joint ventures that occurred between players in the recent past have helped the companies strengthen their market presence. For example, Eli Lilly and Boehringer Ingelheim make Jardiance together, which is a very popular SGLT2 class drug.
  • A new study on Jardiance reflects that the drug helps in reductions in kidney disease and eliminates the risk of Cardiovascular diseases.

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5.1 By Drug
5.1.1 Sodium - glucose cotransport -2 (SGLT-2) inhibitor (Value and Volume 2012-2024) Invokana (Canagliflozin) Jardiance (Empagliflozin) Farxiga/Forxiga (Dapagliflozin) Suglat (Ipragliflozin)
5.2 By Geography
5.2.1 Asia - Pacific Japan (Value and Volume 2012-2024) South Korea (Value and Volume 2012-2024) China (Value and Volume 2012-2024) India (Value and Volume 2012-2024) Australia (Value and Volume 2012-2024) Vietnam (Value and Volume 2012-2024) Malaysia (Value and Volume 2012-2024) Indonesia (Value and Volume 2012-2024) Philippines (Value and Volume 2012-2024) Thailand (Value and Volume 2012-2024) Rest of Asia - Pacific (Value and Volume 2012-2024)
6.1 Type-1 Diabetes population (2012-2024)
6.2 Type-2 Diabetes population (2012-2024)
7.1.1 Eli Lilly
7.1.2 Janssen Pharmaceuticals
7.1.3 Boehringer Ingelheim
7.1.4 AstraZeneca
7.1.5 Bristol Myers Squibb
7.2.1 Eli Lilly
7.2.2 Janssen Pharmaceuticals
7.2.3 Boehringer Ingelheim
7.2.4 AstraZeneca

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Eli Lilly
  • Janssen Pharmaceuticals
  • Boehringer Ingelheim
  • AstraZeneca
  • Bristol Myers Squibb